A breakthrough approach to resolving this translational gap has now been pioneered by a research team led by Professor Sanguk Kim at POSTECH’s Department of Life Sciences and Graduate School of Artificial Intelligence. This multidisciplinary team, including Dr. Minhyuk Park, Mr. Woomin Song, and Mr. Hyunsoo Ahn, has developed an innovative machine learning framework that leverages biological differences between species to forecast drug toxicity more accurately in humans. Their findings, recently published in the prestigious journal eBioMedicine, set a new standard for preclinical drug safety evaluation by focusing on the fundamental genotype-phenotype disparities that exist between humans and experimental models.

At the core of this novel methodology is the concept of “Genotype-Phenotype Difference” (GPD)—the inherent biological variations between genomes and resulting phenotypes across species. Recognizing that genetic targets of drugs regulate cellular behavior differently in animal models compared to humans, the team constructed a predictive system that integrates three pivotal biological dimensions: gene essentiality, tissue-specific gene expression patterns, and gene network connectivity. Gene essentiality reflects the criticality of gene function for cell survival; tissue-specific expression profiles determine where and how genes operate within different biological contexts; and network connectivity maps the complexity of gene interactions that underpin functional pathways.

Empirical validation of the model was conducted on an extensive dataset encompassing 434 drugs flagged as hazardous and 790 drugs that successfully passed human trials. The results revealed a robust association between GPD attributes and clinical drug failure due to toxicity. Remarkably, the machine learning model demonstrated a substantial leap in predictive accuracy relative to traditional chemical structural analyses of drugs. Quantitatively, the model improved the area under the precision-recall curve (AUPRC) from 0.35 to 0.63 and achieved a receiver operating characteristic area under the curve (AUROC) of 0.75, compared to a near-chance 0.50 baseline for conventional approaches. This indicates a significant reduction in false positives and an enhanced ability to identify truly toxic therapeutics.

Beyond just retrospective assessment, the team put their AI framework to a stringent chronological validation test. By training the model exclusively on drug data available up to 1991, it successfully predicted, with 95% accuracy, drugs that were subsequently withdrawn from the market post-1991 due to unforeseen toxicity. This temporal robustness underscores the practical utility of the model in real-world drug surveillance and early safety screening, enabling pharmaceutical companies to flag at-risk candidates before costly and ethically fraught human trials commence.

This research marks a transformative step forward by scientifically quantifying and incorporating interspecies biological differences that have been largely overlooked or difficult to model within existing drug development pipelines. Traditionally, translational failures stem from oversimplified assumptions that animal model responses directly reflect human biology. However, the nuanced genotype-phenotype relationships encoded within each species’ genome influence cellular responses to pharmacological agents in a context-dependent manner, which this framework elucidates and harnesses to refine predictions of drug safety.

By adopting this GPD-centric approach, pharmaceutical research and development can realize multiple benefits. First, it promises to considerably diminish the pipeline attrition rate caused by late-stage toxicity, which is a major contributor to exorbitant costs, time delays, and ethical concerns in drug discovery. Second, it offers a mechanism to safeguard patients by preemptively identifying pharmaceuticals likely to cause harmful side effects upon human exposure. Third, as biological datasets continue to expand—spanning genomic annotations, transcriptomic profiles, and protein interaction networks—the predictive reliability and scope of this model are poised to grow exponentially.

Professor Sanguk Kim emphasized the pioneering nature of their work, noting, “This is the first attempt to incorporate differences in genotype-phenotype relationships for drug toxicity prediction. Our framework enables early identification of high-risk drugs in clinical development.” Co-first authors Dr. Minhyuk Park and Mr. Woomin Song echoed the practical impact: “The human-centered toxicity prediction model will be a very practical tool in new drug development. We anticipate that pharmaceutical companies will be able to screen out high-risk drugs in advance at the preclinical stage, thereby improving development efficiency.”

The strategic integration of advanced machine learning with deep biological insights represented by this study exemplifies the future direction of translational medicine and computational biology. Moving beyond purely chemical descriptors, this approach navigates the complex systems biology underlying drug responses across species, opening avenues towards more reliable and ethical drug discovery processes. Moreover, this method aligns with the overarching imperative of precision medicine—tailoring therapeutic strategies to the unique biological contexts of individual patients, beginning with a better understanding of species-specific genetic and phenotypic nuances.

Supported by the National Research Foundation of Korea, the Ministry of Science and ICT, the Medical Device Innovation Center, and the Synthetic Biology Human Resources Development Program, this research serves as a pioneering example of how interdisciplinary collaboration can accelerate medical innovation. By bridging the critical translational gap, this technology not only has the potential to revolutionize pharmaceutical pipelines worldwide but also offers hope for safer, more effective therapeutics that benefit patients globally.

As the pharmaceutical industry increasingly adopts such sophisticated machine learning tools, the hope is that catastrophic clinical trial failures will become a rarity rather than a distressing norm. Ultimately, this innovative framework underscores the vital role of understanding biological diversity and leveraging computational power, offering a paradigm shift in predicting drug toxicity and safeguarding human health.

Subject of Research: Drug toxicity prediction and genotype-phenotype differences between preclinical models and humans.

Article Title: Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans

News Publication Date: 28-Oct-2025

Web References: DOI Link

Image Credits: POSTECH

Keywords: Health and medicine, Drug therapy, Drug safety, Clinical medicine, Translational research, Translational medicine, Species interaction, Adaptive systems, Artificial intelligence, Deep learning, Computer science, Machine learning, Biological models, Animal models

Microglia, a specialized subset of brain cells, perform essential functions akin to vigilant sentinels in the complex landscape of the central nervous system. They continuously survey the brain environment for pathogens and initiate anti-inflammatory responses to eliminate harmful entities. Moreover, these cells are integral in maintaining the balance and connectivity of neurons, supporting optimal brain function throughout adulthood. Understanding the dynamics of microglia during embryonic brain development is crucial, and Sandra Siegert’s research group is at the forefront of investigating their role in relation to neurons during these formative stages.

In their latest study, recently published in the Journal of Neuroinflammation, the Siegert group introduces an avant-garde brain organoid model that uniquely incorporates microglia. This pivotal development enables a more realistic simulation of inflammatory reactions and provides crucial insights into how these responses can be managed therapeutically. The presence of microglia in the organoid model not only adds complexity but also enhances the relevance of findings related to neuroinflammation and its treatment.

Rubella, commonly recognized as “German Measles,” manifests as mild illness in children and adults, characterized by a rash that spreads across the body. However, if pregnant individuals become infected with the virus, it poses significant risks, potentially leading to severe fetal brain malformations and an increased likelihood of developing schizophrenia in later life. The classification of Rubella as a “TORCH-infection” underlines the importance of studying its effects on embryonic brain development to mitigate long-term negative outcomes.

Researching the impact of viral infections on human brain development is essential. A team led by PhD student Verena Schmied, under the guidance of Professor Sandra Siegert, employed retinal organoids—established models with specific developmental trajectories and cellular architectures—to provide answers. These 3D structures, derived from reprogrammed human skin cells transformed into pluripotent stem cells, mimic key aspects of early fetal brain development, highlighting the intricacies of normal and abnormal brain trajectories.

Recent findings indicate that previous models lacked the incorporation of microglia, which typically appear early in development. The Siegert group’s innovation of including microglia within these retinal organoids has proven effective. By utilizing advanced imaging techniques, the integration of microglia was successfully confirmed, showcasing their distinctive bright pink appearance against the blue-stained neurons. This realization marked a significant milestone for the researchers, illustrating the complexity and functionality of the developed organoid system.

The research team subsequently sought to understand how their organoids responded to viral infections. They simulated the viral infection using a synthetic molecule that is recognized as a viral component, allowing a comparative analysis between organoids with and without microglia. The results revealed a noteworthy response; viral infection led to a disruption of microglial function, initiating an inflammatory response characterized by excessive neuron proliferation. This imbalance raises concerns about the proper establishment of neuronal circuits, potentially culminating in neurodevelopmental disorders.

The relevance of microglia in this model underscores the necessity of including these cells in organoid research. The inflammatory responses triggered by viral infections, which the microglia aim to address, have profound implications for neurodevelopment. Without microglia in the system, critical responses—such as the detrimental effects of inflammation on neuronal assembly—would go unnoticed. This realization expresses the significance of utilizing microglia-containing organoids in research, emphasizing their role in accurately reflecting inflammatory conditions.

In light of there being no specific antiviral treatment for Rubella, aside from anti-inflammatory medications like ibuprofen, the Siegert group explored the effects of ibuprofen on the developing brain within their organoid models. When administered to the virus-infected organoids, ibuprofen demonstrated a capacity to mitigate inflammatory changes, consequently restoring a normal neuronal environment. Notably, this protective effect was contingent upon the presence of microglia, indicating that the anti-inflammatory action of ibuprofen is profoundly influenced by these cells’ signaling pathways.

The findings of this research are pivotal, particularly in addressing the “off-label” use of common analgesics like ibuprofen and paracetamol in pregnant women. Despite the established safety of these medications for adults, their effects during pregnancy remain largely untested due to ethical, financial, and legal complexities surrounding clinical trials. The uncertainty surrounding their usage has heightened the importance of developing realistic organoid models that contribute to our understanding of drug effects on embryonic development.

Through encompassing microglia, the Siegert group’s innovative organoid model not only enhances our understanding of viral infections and inflammatory responses but also serves as a new platform for future investigations. Their work could lead to safer testing of medications for pregnant individuals, ultimately aiming to reduce risks associated with virulent diseases like Rubella. Thus, the study underscores the necessity of developing highly representative models in biomedical research that can better inform clinical practice and improve patient outcomes.

The implications of this research extend beyond immediate findings, potentially reshaping the landscape of drug testing and safety for expectant mothers. As the understanding of microglia and their roles in neurodevelopment continues to evolve, the future of organoid technology promises innovative pathways for exploring complex interactions in the human brain. The thorough investigation of these elements holds the potential to guide the development of safe therapeutic interventions for vulnerable populations, particularly pregnant women, thereby improving maternal and fetal health outcomes in an era of increasing medical complexity.

Subject of Research: Lab-produced tissue samples focusing on the integration of microglia within retinal organoids during viral infections.
Article Title: Microglia determine an immune-challenged environment and facilitate ibuprofen action in human retinal organoids.
News Publication Date: 3-Apr-2025.
Web References: DOI 10.1186/s12974-025-03366-x
References: Journal of Neuroinflammation.
Image Credits: © Schmied et al.
Keywords: Neuroscience, Glia, Microglia, Organoids, Drug Development, Human Brain Models, Pregnancy, Inflammation, Viral Infections.